HIKAL
|
HIKAL Last 5 Year Cashflow Statement History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Profit Before Tax | ₹96 Cr | ₹105 Cr | ₹219 Cr | ₹206 Cr | ₹142 Cr |
Adjustment | ₹175 Cr | ₹163 Cr | ₹126 Cr | ₹127 Cr | ₹136 Cr |
Changes In working Capital | ₹-53 Cr | ₹76 Cr | ₹19 Cr | ₹-58 Cr | ₹46 Cr |
Cash Flow after changes in Working Capital | ₹217 Cr | ₹344 Cr | ₹364 Cr | ₹276 Cr | ₹325 Cr |
Cash Flow from Operating Activities | ₹187 Cr | ₹315 Cr | ₹294 Cr | ₹229 Cr | ₹285 Cr |
Cash Flow from Investing Activities | ₹-174 Cr | ₹-292 Cr | ₹-284 Cr | ₹-156 Cr | ₹-164 Cr |
Cash Flow from Financing Activities | ₹-27 Cr | ₹-7.68 Cr | ₹-5.56 Cr | ₹-97 Cr | ₹-101 Cr |
Net Cash Inflow / Outflow | ₹-14 Cr | ₹15 Cr | ₹3.80 Cr | ₹-24 Cr | ₹20 Cr |
Opening Cash & Cash Equivalents | ₹27 Cr | ₹11 Cr | ₹7.64 Cr | ₹32 Cr | ₹11 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
Effect of Foreign Exchange Fluctuations | - | - | - | - | - |
Closing Cash & Cash Equivalent | ₹13 Cr | ₹27 Cr | ₹11 Cr | ₹7.64 Cr | ₹32 Cr |
Compare Cashflow Statement of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹4,646.6 Cr | 5.1% | 5.2% | 28.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | 0.6% | -2.1% | 16.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹163,010.0 Cr | 4.3% | 6.5% | 63.9% | Stock Analytics | |
CIPLA | ₹118,905.0 Cr | 3.6% | 0.2% | 2.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,523.0 Cr | 3% | -8.4% | 0% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,015.0 Cr | 3.2% | -1% | 27.4% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | 5.1% |
5.2% |
28.1% |
SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses